1. Home
  2. UBCP vs ACET Comparison

UBCP vs ACET Comparison

Compare UBCP & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

UBCP

United Bancorp Inc.

N/A

Current Price

$13.25

Market Cap

80.1M

Sector

Finance

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$0.56

Market Cap

93.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UBCP
ACET
Founded
1902
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.1M
93.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UBCP
ACET
Price
$13.25
$0.56
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
3.3K
1.8M
Earning Date
11-06-2025
11-05-2025
Dividend Yield
6.89%
N/A
EPS Growth
N/A
N/A
EPS
1.31
N/A
Revenue
$30,516,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.59
N/A
P/E Ratio
$10.24
N/A
Revenue Growth
4.40
N/A
52 Week Low
$12.25
$0.45
52 Week High
$15.64
$1.13

Technical Indicators

Market Signals
Indicator
UBCP
ACET
Relative Strength Index (RSI) 58.24 35.71
Support Level $13.21 $0.53
Resistance Level $13.40 $0.70
Average True Range (ATR) 0.20 0.06
MACD 0.06 0.00
Stochastic Oscillator 100.00 17.45

Price Performance

Historical Comparison
UBCP
ACET

About UBCP United Bancorp Inc.

United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. Through its subsidiary (Unified Bank), the company provides a broad range of banking and financial services, which includes accepting demand, savings, and time deposits and granting commercial, real estate, and consumer loans. It serves customers in Belmont, Harrison, Jefferson, Tuscarawas, Carroll, Athens, Hocking, and Fairfield counties and the surrounding localities. The bank also operates in Marshall County West Virginia.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: